Celator Pharmaceuticals Inc

Celator Pharmaceuticals — Investor Day (July 2014)

138 slides from Celator Pharmaceuticals's investor day presentation, Jul 17, 2014

  1. Slide 1: Celator Pharmaceuticals Analyst Day

    a *Celator fos Pharmaceuticals Analyst Day July 17, 2014

  2. Slide 2: Safe Harbor

    Safe Harbor To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securit

  3. Slide 3: Agenda

    Agenda 9:00 – 9:10 AM: Welcome & Introduction Scott Jackson Chief Executive Officer 9:10 – 9:40 AM: CombiPlex & Why It Is Relevant and Important Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Officer 9:40 – 10 :0 0 AM: Acute Myeloid Leukemia – Defining Patient Populations and Current St

  4. Slide 4: Agenda

    Agenda 10:50 – 11:05 AM: Ongoing and Planned Clinical Studies of CPX - 351 Dr. Arthur Louie Chief Medical Officer 11:05 – 11:25 AM: LLS Commitment to CPX - 351 Dr. Louis J. DeGennaro, Ph.D, Leukemia and Lymphoma Society ® , Interim President and CEO 11:25 – 11 :45 AM: CPX - 351 Commercialization Pla

  5. Slide 5: Welcome & Introduction

    Welcome & Introduction Scott Jackson Chief Executive Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 5

  6. Slide 6: Our mission: improve and extend lives of cancer patients

    Front Cover Slide Our mission: To improve and extend the lives of patients with cancer

  7. Slide 7: A Pioneer in Development of Cutting Edge Technologies

    A Pioneer in Development of Cutting Edge Technologies • Although combination therapy is and will remain the cornerstone of therapy for most cancer patients, traditional strategies to combine drugs fall short of realizing the full potential of combination therapy • CombiPlex ® is a combination - opti

  8. Slide 8: Celator's Proprietary Oncology Pipeline

    Celator’s Proprietary Oncology Pipeline 8 CPX - 1 Irinotecan:Floxuridine CPX - 351 Cytarabine:Daunorubicin CPX - 8 (HDPN) Taxane Nanoparticle Research Preclinical Phase 1 Phase 2 Proprietary Technology Platforms Phase 3 Colorectal Cancer Secondary Acute Myeloid Leukemia (Ongoing) Solid Tumors Novel

  9. Slide 9: Building a Broad Pipeline from the CombiPlex Platform

    Building a Broad Pipeline from the CombiPlex ® Platform • Why CombiPlex is relevant and important • Understanding CombiPlex and how it works • Plans to advance CombiPlex and widen its application to molecularly targeted therapies • Combinations targeting signaling pathways (i.e. inhibitors of PI3K/A

  10. Slide 10: AML and Opportunity

    AML and CPX - 351 Opportunity • Understanding the AML market, in particular secondary AML, and current treatment options • Review of the Phase 1 and 2 studies, with discussion about the key aspects/endpoints of the Phase 3 study • The Leukemia & Lymphoma Society ® and the Therapy Acceleration Progra

  11. Slide 11: Phase 3 Study Design in sAML

    CPX - 351 Phase 3 Study Design in sAML 11 Eligibility Confirmation of sAML according to the World Health Organization (WHO) criteria with certain exclusions Age 60 - 75 years Able to tolerate intensive chemo PS 0 - 2 Randomization CPX - 351 7+3 1:1 Randomization Follow - up 150 patients 150 patients

  12. Slide 12: Advantages of the Phase 3 Study

    Advantages of the CPX - 351 Phase 3 Study • AML is heterogeneous; single arm studies used to design Phase 3 studies may not be predictive • Two randomized, controlled clinical studies were conducted to identify a patient population, secondary AML, to pursue in Phase 3 • Patient eligibility in the Ph

  13. Slide 13: Upcoming Endpoints in the Phase 3 study

    What are the Upcoming Endpoints in the Phase 3 study? 13 Metric Endpoint Phase II (based on Phase 3 eligibility, n=58) Phase III Target (approx.) Timing of Data CR+CRi Secondary 73.7% vs 42.1% 20% 2Q2015 Overall Survival Primary HR=0.40, p=0.004 HR=0.635 1Q2016 • A positive Phase 3 result can be ach

  14. Slide 14: CombiPlex: Why It Is Relevant and Important

    CombiPlex ® Why It Is Relevant and Important Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 14

  15. Slide 15: Key Objectives for Technology Update

    Key Objectives for Technology Update Why CombiPlex ® is relevant and important Understanding CombiPlex ® and its advantages Advancing CombiPlex ® to widen its application 15

  16. Slide 16: Future of Anti-Cancer Combination Therapies: The Promise

    Future of Anti - Cancer Combination Therapies: The Promise 16

  17. Slide 17: Future of Anti-Cancer Combination Therapies: The Problems

    Future of Anti - Cancer Combination Therapies: The Problems

  18. Slide 18: Enhancing Efficacy Profile of Drug Combinations

    Enhancing Efficacy Profile of Drug Combinations The Solution = CombiPlex ® Control drug ratios after injection • Nano - scale liposomes and nanoparticles engineered to:  Stably encapsulate synergistic drug ratios  Harmonize PK through controlled release to maintain optimal ratio in vivo  Provide

  19. Slide 19: CombiPlex Delivers Sustained, Synergistic Drug Ratios

    CombiPlex ® Delivers Sustained, Synergistic Drug Ratios to Increase Anti - tumor Potency Identify drug combinations that exhibit ratio - dependent synergy Fix desired synergistic ratio in effective drug delivery vehicle Deliver and maintain synergistic drug ratio in vivo Increased anti - tumor poten

  20. Slide 20: CombiPlex Delivers the Right Ratio to the Tumor

    CombiPlex ® is Critical to Delivering the Right Ratio, to the Tumor, for Prolonged Periods of Time Inject Inject 24 hours CombiPlex ® Maintains Ratio 1 hour Free Drug Cocktail: Ratio changes rapidly 20

  21. Slide 21: Delivery Systems are Key Enablers of CombiPlex

    Delivery Systems are Key Enablers of CombiPlex ® Proprietary Liposome and Nanoparticle Platforms Provide Means for Synchronizing Combination PK • Lipid membrane controls drug release rates • Provide differential release control of water soluble and amphipathic drugs • Proprietary active drug loading

  22. Slide 22: Proof of CombiPlex Technology Concept Case Study

    Proof of CombiPlex ® Technology Concept CPX - 351 Case Study Proof - of - concept established with approved cytotoxic drug combinations supports application of CombiPlex ® to wide array of drug combinations 22

  23. Slide 23: In Vitro Screening Reveals Ratio-dependent Synergy

    CPX - 351 - In Vitro Drug Combination Screening Reveals Ratio - dependent Synergy for Cytarabine:Daunorubicin Cytarabine:Daunorubicin molar ratio of 5:1 maximizes synergy and minimizes antagonism in vitro 1:10 1:5 1:1 5:1 10:1 HCT-116 Colon 0.8 0.7 0.8 0.8 0.8 SW620 Colon 1.0 0.6 0.8 0.7 0.6 Nalm-6

  24. Slide 24: Elevated Exposure to Synergistic Drug Ratios

    Hours after injection 0 10 20 30 40 50 Plasma drug concentration (  g/ml) 0.1 1 10 100 1000 Hours after injection 0 5 10 15 20 25 CPX-351 Cyt:Daun Molar Ratio 1 10 Cyt Daun Cyt Daun Key Features Underlying CPX - 351 Efficacy Improvements Provided by CombiPlex ® Elevated exposure to synergistic drug

  25. Slide 25: Prolonged Drug Exposure at Tumor Site

    Hours After Administration 0 20 40 60 80 100 120 140 160 180 Bone Marrow Cytarabine (  g/ml) 0 1 2 3 CPX-351 Free drug cocktail Free Drug CPX - 351 ;allways Prolonged drug exposure at tumor site Key Features Underlying CPX - 351 Efficacy Improvements Provided by CombiPlex ® 25

  26. Slide 26: Selective Delivery to Tumor Cells

    Cytarabine Leukemic Cells Normal BM Cells pmol/10 6 cells 0 5 10 15 20 25 30 Daunorubicin Leukemic Cells Normal BM Cells 0 5 10 15 20 25 Liposomes Leukemic Cells Normal BM Cells 0 50 100 150 200 250 Selective delivery to tumor cells pmol Cytarabine/10 6 cells Key Features Underlying CPX - 351 Effica

  27. Slide 27: Dramatic Preclinical Efficacy Improvements

    0 20 40 60 80 0 20 40 60 80 100 Dramatic Preclinical Efficacy Improvements WEHI - 3B Monomyelocytic Leukemia Days post cell inoculation % Survival Saline Control CPX - 351 12:5.3 mg/kg Cyt:Daun Free Drugs 300:4.5 mg/kg Cyt:Daun MTD MTD 27

  28. Slide 28: Significant Improvement in Overall Survival in 2 Randomized Studies

    Overall Survival 0% 20% 40% 60% 80% 100% 0 3 6 9 12 15 Months from randomization CPX - 351 Median = 6.6 months Salvage Median = 4.2 months CPX - 351 Demonstrated Significant Improvement in Overall Survival in 2 Randomized, Controlled Studies 0% 20% 40% 60% 80% 100% 0 12 24 36 48 Months from randomiz

  29. Slide 29: Important Lessons Learned

    Important Lessons Learned from CPX - 351 • In vitro informatics on drug ratio - dependent synergy can be translated in vivo using appropriately designed delivery systems • CombiPlex ® results from preclinical models are representative of human experience • PK parameters scaled allometrically from mi

  30. Slide 30: Relevance of CombiPlex for Molecularly Targeted Agent Combinations

    Relevance of CombiPlex ® Technology For Molecularly Targeted Agent Combinations 30

  31. Slide 31: Trends in Development of Molecular Targeted Agents

    Trends in Development of Molecular Targeted Agents: Important Role of Combinations • Single molecularly targeted agents often have modest or transient antitumor activity • Tumor cell survival is often dictated by multiple targets • Emergence of resistance is more likely to result from targeting one

  32. Slide 32: Rationale for Role of Drug Delivery in Targeted Agent Combinations

    Rationale for Role of Drug Delivery in Development of Targeted Agent Combinations • Many combinations will require simultaneous target inhibition • Need for harmonized PK and tumor cell exposure • Conventional dosing formats unable to coordinate exposure due to differential and independent drug dist

  33. Slide 33: CombiPlex Path vs Traditional Path

    Go/No Go CombiPlex ® Path Drug A Drug B In Vitro : Identify Synergistic Ratio Formulate at Synergistic Ratio Preclinical PoP at Synergistic Ratio Phase 1 Combo with Synergistic Ratio to MTD Phase 2 Combo with Synergistic Ratio at MTD Months Traditional Path Go/No Go Drug A Drug B In Vitro Preclinica

  34. Slide 34: Parallel Paths to Generate Preclinical CombiPlex Data Packages

    Parallel Paths being Pursued to Generate Preclinical CombiPlex ® Data Packages with Targeted Agents Develop independently • Generate data with CombiPlex for 3 targeted combination regimens • In addition, this allows development of single agent nanoparticle pro - drugs for 2 agents Objectives: 1. Est

  35. Slide 35: Targeted Agent Pilot Studies for CombiPlex

    Targeted Agent Pilot Studies for CombiPlex ® • Generate data demonstrating feasibility and benefits provided by CombiPlex for combinations of molecularly targeted agents to attract R&D collaborations and/or generate product candidates for internal development • Identify 3 targeted agent combinations

  36. Slide 36: Value-drivers / Benefits of CombiPlex

    36 Value - drivers / Benefits of CombiPlex ® Provide the Starting Point for Future Development Priorities CombiPlex® Platform Benefits / Potential Benefits Efficacy: Locking in fixed ratio combinations Efficacy: Greater target selectivity Toxicity: Lower collateral selectivity (e.g., cardio) Potenti

  37. Slide 37: Identifying Opportunities to Leverage CombiPlex Technology

    Identify Initial List of ~20 Potential Expansion Opportunities Based on established or potential agent synergy Criteria for Prioritizing Summarize Opportunities, Sequencing 1 2 3  Scientific  Clinical  Market / Competitive  Regulatory  Intellectual Property  Financial and Other Short - list fo

  38. Slide 38: Combinations Identified for Molecularly Targeted Agents

    Combinations Identified for CombiPlex ® Application to Molecularly Targeted Agents Combinations of epigenetic modulators • Histone deacetylase inhibitors; plus • Hypomethylating agents (e.g. azacitidine, Celgene) Combinations targeting major signaling pathways • Inhibitors of PI3K/AKT/mTOR pathway (

  39. Slide 39: Leveraging CombiPlex to Build a Pipeline of Targeted Agents

    Leveraging CombiPlex ® to Build a Pipeline of Targeted Agents • In vitro drug ratio dependency can be translated in vivo utilizing drug delivery vehicles, resulting in dramatic improvements in efficacy; preclinical results also translate to clinical improvements • Efficient iterative product generat

  40. Slide 40: AML: Defining Patient Populations and Current Standard of Care

    Acute Myeloid Leukemia - Defining Patient Populations and Current Standard of Care Dr. Richard Stone Director, Adult Acute Leukemia Program, Dana Farber Cancer Institute Celator Pharmaceuticals Analyst Day, July 17, 2014 40

  41. Slide 41: AML: Key Points

    41 AML: Key Points Richard M. Stone, MD Director, Adult Leukemia Program Dana - Farber Cancer Institute and Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA

  42. Slide 42: AML: What is it and how did it get there?

    42 AML: What is it and how did it get there?  Unbridled proliferation of hematopoietic stem cells (myeloid lineage) resulting in marrow failure and patient death unless successfully treated  Risk factors: AGE, prior chemo for other cancers, ionizing radiation, industrial solvents (last 3 probably

  43. Slide 43: Key Points from de novo AML genome atlas

    43 Key Points from de novo AML genome atlas  AML genomes have fewer mutations than most other adult cancers (n=13, 5 of which are among the 23 recurrently mutated genes)  9 Key categories: – transcription - factor fusions (18%) – nucleophosmin ( NPM1 ) (27%) – tumor - suppressor genes (16%) – DNA

  44. Slide 44: AML: FAB Classification

    44 AML: FAB Classification • M0: Cytochem neg; myeloid Ag on flow • M1: Peroxidase pos. • M2: Perox pos.; some differentiation • M3: Acute Promyelocytic Leukemia • M4: Acute Myelomonocytic Leukemia (perox and NSE pos.) • M5: Acute Monocytic Leukemia (NSE pos) • M6: Acute Erythroleukemia • M7: Acute

  45. Slide 45: WHO Classification of AML

    45 WHO Classification of AML • AML with recurrent cytogenetic translocations – t(8;21), t(15;17), 11q23, inv 16 or t(16;16) • AML with multilineage dysplasia – prior MDS • AML, therapy - related – alkylating agent, epipodophyllotoxin - related • 20% blasts, not 30%, constitutes AML, not RAEB - T

  46. Slide 46: Current Risk Assessment in AML

    46 Current Risk Assessment in AML Key Prognostic Data in AML in 2013 Patient age Cytogenetics / karyotype Primary versus secondary disease (secondary = post - antecedent hematologic disorder, or therapy - related) Molecular studies: • FLT3 ITD (internal tandem duplication) mutation Unfavorable • NPM

  47. Slide 47: Older Patients With AML Continue to Have Inferior Outcomes

    47 Older Patients With AML Continue to Have Inferior Outcomes • Data are based on CALGB & MRC trials for which adults of all ages were eligible Age group Complete remission rate (with “3&7” - like regimens) Early mortality Disease - free survival Long - term overall survival Median survival <60 year

  48. Slide 48: Why Older Patients Experience Inferior Outcomes

    48 Why Do Older Patients With AML Experience Inferior Outcomes? • Decreased host tolerance of intensive therapy – Impaired hematopoietic stem cell reserve – Presence of comorbid diseases – Decreased chemotherapy clearance • Increased resistance of disease to therapy – Ratio of favorable (eg, t[8;21]

  49. Slide 49: ELN Guidelines: AML Prognostic Subgroups

    49 European Leukemia Net (ELN) Guidelines: AML Genetic - Cytogenetic Prognostic Subgroups Döhner H et al, Blood 2010; 115(3):453 - 474 Genetic Risk Group Survival Subset Favorable 65% • t(8;21)(q22;q22); RUNX1 - RUNX1T1 • inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB - MYH11 • Mutated NPM1 without

  50. Slide 50: Consolidation: DFS Benefit Only in Patients <60 Years

    50 100 80 60 40 20 0 ...12…...24…...36…...48…...60…...72….. 84 . ...12…...24…...36…...48…...60…...72….. 84 . Patients in Remission (% ) Age < 60 Age > 60 3 g/m 2 = 156 400 mg/m 2 = 156 100 mg/m 2 = 155 P = 0.0007 3 g/m 2 = 31 400 mg/m 2 = 50 100 mg/m 2 = 48 P = 0.22 Consolidation: DFS Benefit Only i

  51. Slide 51: AML Therapy for Patients <60 Years Old

    51 AML Therapy for Patients <60 Years Old Guidelines • Standard induction chemo: “3+7”  Daunorubicin 60 - 90 mg/m 2 /d x 3 (or idarubicin 12 mg/m 2 /d x 3)  Cytarabine 100 - 200 mg/m 2 /d x 7 continuous infusion • Post - remission (consolidation) therapy:  If poor cytogenetics: AlloSCT  If favor

  52. Slide 52: Optimal Induction Approach in Older Patients With AML

    52 What is the Optimal Induction Approach in Older Patients With AML? • Standard induction : 3&7 (if patient likely to tolerate) – Daunorubicin 45 - 90 mg/m 2 /d x 3d – Cytarabine 100 - 200 mg/m 2 /d x 7d by continuous infusion 1 – Idarubicin or mitoxantrone are not better than daunorubicin 2 – Addi

  53. Slide 53: Selected Lower-Intensity Approaches in Older Patients

    53 Selected Lower - Intensity Approaches in Older, Poor Prognosis Patients With AML – Clofarabine 30 mg/m 2 /d x 5d (n = 112) (nucleoside analogue) 1  Median age 71 years, 36% with prior MDS  38% CR, 8% CRp (seen even with several risk factors)  Early death rate = 10% – Decitabine 20 mg/m 2 /d x

  54. Slide 54: AML: Where We Are Today

    54 AML: Where We Are Today • Under age 55 - 60 years: aggressive induction (3 [dauno 90] +7) and consolidation with high - dose chemo (HDC)/HDC with autologous peripheral blood stem cell transplant (PBSCT) or alloSCT (sibling or matched unrelated donor [MUD])  Post - CR rx moving toward alloSCT in

  55. Slide 55: Secondary AML

    55 Secondary AML Definition: AML occurring after prior MDS or after chemo for another cancer New pathophysiology insight - preexisting p53 mutation in HSC clones occur by chance but may be selected for by chemo Prognosis usually poor (basically like that of older adults), but if favorable chromos ca

  56. Slide 56: Secondary AML: Same Mutations as MDS Plus Others

    56 Sec AML: Same Mut as MDS Plus Others Walter et al, NEJM 2012

  57. Slide 57: Trial Design

    57 Trial Design - 1 • Newly diagnosed patients with secondary AML randomized to: – amonafide 600 mg/m 2 /d IVCI over 4h qd, d 1 - 5, plus ara - C 200 mg/m 2 /d IVCI, d1 - 7 OR – daunorubicin 45 mg/m 2 /d over 30 min d 1 - 3 plus ara - C 200 mg/m 2 /d IVCI, d1 - 7 • If day 14 marrow positive, a 2 nd

  58. Slide 58: Patient Demographics

    58 Patient Demographics Amonafide/Ara - C Dauno/Ara - c Age(median) 64.5 63 Race (white) 83% 87% Sex (female) 50% 42% AML w/antecedent MDS 11% 9% WBC>20 18% 19% Elevated LDH 62% 60% Intermediate risk Cytogenetics 34% 33% 433 pts randomized; 23 countries

  59. Slide 59: Primary Endpoint: Complete Remission Rate

    59 Primary Endpoint: Complete Remission Rate Amonafide/ara - C (n=216) Daunorubicin/ara - C (n=217) 46% 45% 20.4% 12.4% CR rate 30 d mortality

  60. Slide 60: CR Rate by Cytogenetic Risk

    60 CR Rate by Cytogenetic Risk Amonafide/ara - C Daunorubicin ara/C Favorable n=9 100% 88% Int n=146 53% 54% Unfavorable n=173 41% 32% Unknown n=105 43% 46% p=0.001 for overall CR rate by cytogenetic category (Fisher’ s exact test)

  61. Slide 61: Multivariable Analysis for CR Rate

    61 Multivariable Analysis for CR Rate P Value Odds ratio Rx arm 0.69 1.084 Elevated LDH 0.01 0.577 Elevated WBC 0.002 0.403 Therapy - related AML 0.02 0.421 Unfavorable Cytogenetic 0.004 0.540

  62. Slide 62: Survival According to Cytogenetic Risk Group

    62 Survival According to Cytogenetic Risk Group for Patients With t - AML or De Novo AML Treated by German AML Cooperative Group Karyotype n(%) med OS (mo) t - AML (n = 121) AML (n - 1,511) t - AML AML P Fav 29 (24) 306 (20) 27 NR .02 Inter 34 (28) 903 (60) 12 16 .19 Unfav 58 (48) 302 (20) 6 7 .006

  63. Slide 63: Target-ish Rx in AML - I

    63 Target - ish Rx in AML - I • Flavopirodol (combined w chemo) • HSP90 inhibition • NEDD8 inhibition • RAS/MEK inhibition: tipifarib/trametenib • Histone methyltransferase inhib (in MLL re - arranged) • Hedgehog pathway inhibition (combined with chemo) • Proteosome inhibitors (combined with chemo)

  64. Slide 64: Target-ish Rx in AML - II

    64 Target - ish Rx in AML - II • New ‘delivery system’: CPX - 351 • Activation of p53: MDM2 inhib • PLK inhibition • HDAC inhibitors (Upfront S1203 trial) • Nuclear export protein inhibitors • MUC - 1 inhibitors • PIM kinase inhibitors • Bromodomain inhibitors • Immune Checkpoint inhibition • TARGET

  65. Slide 65: If Phase 3 Trial is Positive

    65 If CPX - 351 Phase 3 Trial is Positive • If the primary OS endpoint is positive : extend survival by several months • It will likely become the standard of care for those who would have been eligible for the phase 3 trial (age 60 - 75) - hopefully increased CR will serve as a ‘better bridge to tr

  66. Slide 66: Acknowledgements

    66 Acknowledgements • Clinical Team at DFCI: – Dan DeAngelo, MD, PHD – David Steensma, MD; Martha Wadleigh, MD, Gabi Motyckova, MD, PHD – Ilene Galinsky, NP – Susan Buchanan, PA; Andrian Penicaud, PA, Sarah Cahill, PA, Kat Edmonds, NP • Scientific Team at Dana - Farber/Harvard Cancer Center – Jim Gr

  67. Slide 67: Phase 1 & 2 Clinical Data & the Ongoing Phase 3 Study

    CPX - 351 Phase 1 & 2 Clinical Data & the Ongoing Phase 3 Study Dr. Jeffrey Lancet Section Chief of Leukemia, Department of Malignant Hematology, Moffitt Cancer Center Celator Pharmaceuticals Analyst Day, July 17, 2014 67

  68. Slide 68: Timeline of progress in AML

    Timeline of “progress” in AML 1950s - 1960s 1970s 1980s 1990s 2000s 2010s Daunorubicin Cytarabine Daunorubicin + Cytarabine Idarubicin + Cytarabine High - dose Cytarabine Gemtuzumab Cladribine Vosaroxin CPX - 351 Sapacitabine Midostaurin HMAs HDAC inhibitors

  69. Slide 69: AML survival in older patients

    AML survival: patients ≥ 60 years Burnett et al. Semin Hematol 2006: 43(2):96 - 106 , 0 1 2 3 4 5 6 7 8 0.0 0.2 0.4 0.6 0.8 1.0 Years Survival Probability

  70. Slide 70: Issues delaying development of effective new therapy in AML

    Issues delaying the development of effective new therapy in AML • Discovery of molecular anomalies have not yet translated into clear therapeutic targets • Lack of molecular data applied retrospectively to predict response • Trial Design • Empiric testing in a heterogeneous disease • Especially with

  71. Slide 71: CPX-351 liposome composition

    CPX - 351 • 100 nm bilamellar liposomes • 5:1 molar ratio of cytarabine to daunorubicin • 1 unit = 1.0 mg cytarabine plus 0.44 mg daunorubicin

  72. Slide 72: Pharmacological Basis of CPX-351

    Pharmacological Basis of CPX - 351 CPX - 351 liposome delivers 5:1 molar ratio for >24 hours Hours After Administration 0 20 40 60 80 100 120 140 160 180 Bone Marrow Cytarabine (  g/ml) 0 1 2 3 CPX-351 Free drug cocktail Cytarabine Accumulates and persists in the bone marrow Preferential uptake and

  73. Slide 73: Phase 1 study of CPX-351 in AML

    Phase 1 study of CPX - 351 in AML • First in human study • Relapsed, refractory AML • Dose escalation – planned up to 134 units/m 2 • Primary endpoints – safety, maximum tolerated dose

  74. Slide 74: Phase 1 study: Key Findings

    • Safety • Dose limiting toxicity in 3 of 6 patients at 134 units/m 2 • Congestive heart failure, hypertension, prolonged cytopenias • Other most common grade 3 - 4 toxicities • Rash, liver function abnormalities, • Clinical congestive heart failure in 2 of 23 pts (both with heavy prior anthracyclin

  75. Slide 75: Pharmacokinetics

    Pharmacokinetics 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 0 24 48 72 96 120 144 168 TIME (hr) Cytarabine Daunorubicin Mean plasma concentration after the day 5 infusion among patients receiving 24 units/m^2 CPX-351 (n=3) D & A detectable 7 days at completion of infusion Fixed molar rati

  76. Slide 76: Randomized Phase 2 Trial vs 7+3 in Older Untreated AML

    Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Eligibility • Newly diagnosed • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 (n=84) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 (n=41) Daunorubicin 60 mg/m 2 Cytarabine 100 m

  77. Slide 77: Key demographic features

    Key d emographic f eatures CPX - 351 7+3 n=85 n=41 Gender Male 53 (62.4%) 25 (61.0%) Race Caucasian 76 (89.4%) 39 (95.1%) Risk Standard Risk 28 (32.9%) 14 (34.1%) High Risk 57 (67.1%) 27 (65.9%) Age Group ≥70yrs 34 (40.0%) 15 (36.6%) Median (yrs) 68.0 68.0 AML Type De novo AML 52 (61.2%) 22 (53.7%)

  78. Slide 78: Phase 2 Trial Response Results

    Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Parameter CPX - 351 (n=84) “7+3” Regimen (n=41) CR (%) 41 (48.8) 20 (48.8) CRi (%) 15 (17.9) 1 (2.4) CR + CRi (%) 56 (66.6) 21 (51.2) 60 - d mortality (%) 4 (4.7) 6 (14.6) CR + CRi (%) in s - AML 19 (57.5) 6 (31.6) s - AML median

  79. Slide 79: Phase 2 Overall Survival

    Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML sAML All Patients Overall Survival Overall Survival by treatment arm 0% 20% 40% 60% 80% 100% 0 12 24 36 48 Months from randomization Arm A: CPX - 351 Arm B: 7+3 Deaths / N 58 / 85 27 / 41 Median in Mon s . 14.7 ( 10.6 , 18.1 ) 12.

  80. Slide 80: Safety

    Safety 80 CPX - 351 (n=85) 7+3 (n=41) n (%) n (%) Grade 3/4 Grade 5 Grade 3/4 Grade 5 Febrile Neutropenia 54 (63.5) 0 (0.0) 21 (51.2) 0 (0.0) Infections 60 (70.6) 3 (3.5) 18 (43.9) 3 (7.3) Bacteraemia 30 (35.3) 0 (0.0) 8 (19.5) 0 (0.0) Epistaxis 6 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) Petechiae 1 (1.2) 0 (0

  81. Slide 81: Outcomes with prior hypomethylating agent exposure

    Outcomes in patients with prior hypomethylating agent exposure Prior Hypomethylating Agent Treatment CPX - 351 n=33 (%) 7+3 n=19 (%) +HMA 13 (39%) - HMA 20 (61%) +HMA 7 (37%) - HMA 12 (63%) Responses 7 (54) 12 (60) 2 (29) 4 (33) CR 3 (23) 9 (45) 2 (29) 4 (33) CRi 4 (31) 3 (15) 0 0

  82. Slide 82: Randomized Phase 2 Trial vs Salvage in 1st Relapse AML

    Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Eligibility • 1st Relapse • Initial CR ≥1 month • Ages 18 - 65 • Stratified by European Prognostic Index • PS 0 - 2 CPX - 351 (n=81) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations Salvage (as per investigator

  83. Slide 83: Phase 2 Relapse Results

    Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Overall (n=125) EPI Poor - Risk ( n=85) CPX - 351 (n=81) Salvage (n=44) CPX - 351 (n=56) Salvage (n=29) Response Rate 49.4% 40.9% 39.3% 27.6% 60 - Day Mortality 14.8% 15.9% 16.1% 24.1% EFS (median, mos.) 4.0 1.4 1.9 1.2 OS (median,

  84. Slide 84: Potential reasons for greater benefit in High-Risk AML

    Potential reasons why CPX - 351 has a greater b enefit in High - Risk AML Patients • Altered signaling/cell cycle control checkpoints • 5:1 molar ratio: constant cytarabine excess → daunorubicin DNA damage without blocking cell cycle progression to S - phase where cytarabine action occurs preventing

  85. Slide 85: Randomized Phase 3 Trial vs 7+3 in Older Patients with sAML

    Randomized Phase 3 Trial of CPX - 351 vs “7+3” in Older Patients with sAML Eligibility • Previously untreated sAML or tAML • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 Daunorubicin 60 mg/m 2 Cytarab

  86. Slide 86: Phase II study: sAML Definition Phase II vs Phase III

    CPX - 351 vs 7+3 Phase II study: sAML Definition Phase II vs. Phase III *Patient 12 - 004, originally identified as a de novo patient, was diagnosed with Philadelphia chromosome and was not assessed for response Phase III study will use WHO criteria for confirmation of secondary AML 16 patients adde

  87. Slide 87: What makes the AML-301 study unique

    What makes AML - 301 unique from other phase 3 AML studies? • Based upon a prior randomized study • Based upon a prior study that identified a distinct group of patients found to benefit from CPX - 351 (secondary AML) • Primary endpoint (overall survival) was modeled upon the primary endpoint from s

  88. Slide 88: Endpoints

    Endpoints • Primary • Overall survival with >90% power to detect HR = 0.63 • Detect a 37% decrease in the rate of death with CPX - 351 over the course of the study. • Secondary • Response rate • Event - free survival • 60 day mortality • Leukemia clearance rate

  89. Slide 89: Power calculations

    Power calculations Power Hazard Ratio 70 0.726 75 0.712 80 0.697 85 0.679 90 0.657 93.7 0.635 Arm B Rate 31% 42% Power Arm A Rate (%) Difference (%) Arm A Rate (%) Difference (%) 70 46.5 15.5 57.9 15.9 75 47.4 16.4 58.8 16.8 80 48.4 17.4 59.8 17.8 85 49.6 18.6 60.9 18.9 90 51.0 20.0 62.3 20.3 95 53.

  90. Slide 90: Question & Answer Session & Break

    Question & Answer Session & Break Celator Pharmaceuticals Analyst Day, July 17, 2014 90

  91. Slide 91: Ongoing and Planned Clinical Studies

    Ongoing and Planned Clinical Studies of CPX - 351 Dr. Arthur Louie Chief Medical Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 91

  92. Slide 92: Life Cycle Development

    CPX - 351 Life Cycle Development Extend Use to Other AML and Hematologic Malignancies Indications Treatments CPX - 351 alone CPX - 351 + other drugs High - risk AML Other AML indications AML Special Populations Pre - conditioning prior to HSCT CPX - 351 life cycle management is based on high - level

  93. Slide 93: Life Cycle Development Overview

    CPX - 351 Life Cycle Development – Overview Completed Ongoing Planned First Line Treatment  Older patients – Phase 2 (204 Study)  sAML, older patients – Phase 3  High risk, younger patients – Phase 3 AML 19 X X In discussion Second Line and Later Treatment  1 st relapse, younger patients – Phase

  94. Slide 94: Unfit AML Due to Co-morbidities

    Unfit AML Due to Co - morbidities: Dr. Walter – Fred Hutchinson Cancer Research Center R CPX-351 32u/m 2 Which dose level, 32 u/m 2 or the 64 u/m 2 or both has acceptable treatment-related mortality (<30%) and improves CR rate (>30%) CPX-351 64u/m 2 Phase II in AML or High-risk MDS: üFirst Line AML,

  95. Slide 95: Unfit AML Due to Poor Risk

    Unfit AML Due to Poor Risk: Dr. Cortes - MD Anderson Cancer Center • Newly diagnosed AML at high risk for induction mortality • Unfit AML is estimated to be ~10K patients globally • Typically treated with daunorubicin/cytarabine • Current risk of death is 30 - 50%; objective to lower mortality to <3

  96. Slide 96: Pre-conditioning Prior to HSCT

    Pre - conditioning Prior to HSCT: Dr. Gergis - Cornell • AML and High - risk MDS eligible for bone marrow transplant • Unrelated transplants in Adults with AML ~2.7K patients in the U.S. • Objective is <5% blasts before transplant • With current treatments 40% of patients achieve <5% blasts CPX-351

  97. Slide 97: AML and HR-MDS After HMA Therapy

    AML and HR - MDS After HMA Therapy: Dr. Medeiros - Stanford • AML or high - risk MDS relapsed or refractory to prior hypomethylating agents • MDS and HMA failure is estimated to be ~5 - 6K patients globally • Median survival in AML is 3.4 months and 5.6 months in MDS, CR rate is 20% • Objective is t

  98. Slide 98: Relapsed/Refractory Hematologic Malignancies (COG Pilot Study)

    Relapsed/Refractory Hematologic Malignancies (COG Pilot Study): Dr. Absalon - Cincinnati Children’s Hospital Hypothesis 1. Daunorubicin when administered as CPX - 351 results in less cardiotoxicity compared to standard administration of anthracyclines/anthracenedione 2. Serum biomarkers of cardiotox

  99. Slide 99: Pediatric Leukemia: Pilot Study Rationale

    Pediatric Leukemia: Pilot Study Rationale Mulrooney et al. BMJ 2009;339:b4606 99

  100. Slide 100: Life Cycle Development

    CPX - 351 Life Cycle Development Extend Use to Other AML and Hematologic Malignancies Indications Treatments CPX - 351 alone CPX - 351 + other drugs High - risk AML Other AML indications AML Special Populations Pre - conditioning prior to HSCT CPX - 351 life cycle management is based on high - level

  101. Slide 101: Leukemia and Lymphoma Society Commitment

    Leukemia and Lymphoma Society ® Commitment to CPX - 351 Dr. Louis J. DeGennaro, Ph.D. Leukemia and Lymphoma Society: Interim President and Chief Executive Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 101

  102. Slide 102: What Drives Us

    What Drives Us KEY MESSAGE “You have cancer.” “I have an effective treatment for you.” “You are cured.”

  103. Slide 103: Why It's Important

    Why It’s Important KEY MESSAGE Anyone can get blood cancer

  104. Slide 104: Cures Today, Not Someday

    Cures Today, Not Someday KEY MESSAGE

  105. Slide 105: Confronting a Broad Range of Diseases

    0 10 20 30 40 50 60 70 80 90 0% 20% 40% 60% 80% 100% MM NHL CLL CML MPNs HL ALL (Adults) 83,000/ year 2,800/year Incidence Scale AML MDS ALL (Children) Median 5 - year Survival Rate Median Age at Diagnosis Confronting a Broad Range of Diseases with Diverse Outcomes

  106. Slide 106: Why We're Here: The Patients

    50% of blood cancer patients survive their diagnosis 50% do not survive Access Cures Why We’re Here: The Patients

  107. Slide 107: LLS Research Has Supported Nearly All Innovative Blood Cancer Treatments

    107 Idelalisib (PDUFA review: Sept 11, 2014) Newly approved by FDA in 2013 - 4 LLS Research Has Supported Nearly All Innovative Blood Cancer Treatments

  108. Slide 108: LLS Has Funded Research for 60 Years

    Discovery Development Approval New Therapies! Academic Grants Program 108 Therapy Acceleration Program Total funding to date: $1 billion dollars LLS Has Funded Research for 60 Years

  109. Slide 109: Diligence Questions

    ▪ Unmet medical need - avoiding crowded areas supported by others ▪ Quality of the science and the asset, level of innovation ▪ Competency and enterprise readiness of partner ▪ Value of LLS as a partner More recently: ▪ Strategic fit with LLS research agenda ▪ Potential for a return on investment Di

  110. Slide 110: Celator Partnership

    CPX - 351 Celator Partnership

  111. Slide 111: Why Partner with Celator: Unmet Medical Need

    0 10 20 30 40 50 60 70 80 90 0% 20% 40% 60% 80% 100% MM NHL CLL CML MPNs HL ALL (Adults) 83,000/ year 2,800/year Incidence Scale AML MDS ALL (Children) Median 5 - year Survival Rate Median Age at Diagnosis Why Partner with Celator: Unmet Medical Need

  112. Slide 112: Compelling Phase 2 Results: Fund the Phase 3 Study

    112 Compelling Phase 1 Results: Fund the Phase 2 Study at $4.1 Million

  113. Slide 113: Compelling Phase 2 Results: Fund the Phase 3 Study

    Phase 2 study results versus control: ▪ Doubled the number of patients achieving complete remission ▪ Reduced treatment - related mortality by a factor of 5 ▪ Nearly tripled the number of patients alive at one year Compelling Phase 2 Results: Fund the Phase 3 Study at $5 Million

  114. Slide 114: Measures of Success

    ▪ Direct impact for patients • Changing the standard of care • Demonstrated clinical response throughout the development process • Demonstrated clinical proof of concept ▪ Achieved “expected endpoint” ▪ Partnered Measures of Success

  115. Slide 115: Therapy Acceleration Program Pipeline

    INDICATION(S) PRECLINICAL PHASE I PHASE II PHASE III MDS AML MLL Leukemia AML B - Cell Cancers CTCL DLBCL Leukemia Acute Leukemia AML/MDS Myeloma Acute Leukemia Licensed by B - cell Lymphoma Myeloma Acquired by $100 M partnership Licensed by Recent IPO IPO Therapy Acceleration Program Pipeline

  116. Slide 116: Leukemia & Lymphoma Society: A Better Solution for Patients

    Academic Research Biotech Pharma FDA Patients & Providers Third - Party Payors Research Grants Venture Philanthropy Policy Advocacy Patient Programs Provider Programs Leukemia & Lymphoma Society A Better Solution for Patients

  117. Slide 117: Commercialization Plans

    CPX - 351 Commercialization Plans Derek Miller Chief Business Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 117

  118. Slide 118: Commercial Overview

    CPX - 351 Commercial Overview AML Market Place and Opportunity Commercial Plan for CPX - 351 Value of CPX - 351 in AML and beyond 118

  119. Slide 119: Potential Positioning

    CPX - 351 Potential Positioning* • For Acute Myeloid Leukemia patients who are deemed appropriate to receive intensive myeloablative therapy, CPX - 351 is the foundational treatment that prolongs survival and reduces treatment - related mortality * For Planning Purposes only and pending FDA approval

  120. Slide 120: AML Market Place and Opportunity

    AML Market Place and Opportunity 120

  121. Slide 121: Estimated Proportion of New Leukemia Cases in 2014

    Estimated Proportion of New Cases (%) in 2014 for Types of Leukemia, Adults and Children* in the U.S. AML, 18,860 (36%) CLL, 15,720 (30%) ALL, 6,020 (12%) Leukemia, other, 5,800 (11%) CML, 5,980 (11%) Source: Cancer Facts & Figures, 2014 American Cancer Society; 2014. Total is less than 100% due to

  122. Slide 122: Age-specific Incidence Rates for AML

    Age - specific Incidence Rates for Acute Myeloid Leukemia in the U.S. (All Races, 2006 - 2010) – Median Age at Diagnosis is 66 122 Source: SEER (Surveillance, Epidemiology and End Results) Cancer Statistics Review, 1975 - 2010. National Cancer Institute; 2013. .

  123. Slide 123: Acute Myeloid Leukemia Market

    Acute Myeloid Leukemia Market • Bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets • If left untreated, AML progresses rapidly to death • With treatment • Median Overall Survival <12 months for AML patients • Median Overall Survival 6 - 7 months for Se

  124. Slide 124: Treatment Decisions Based on Whether Patient is Fit

    In Practice, Treatment Decisions Based on Whether Patient Deemed Suitable for Treatment (i.e. “Fit”) Composite Measure of Age, Performance Status, and Comorbidities Treatment/ Therapy Choice Diagnosis “Fit” “Unfit” Low/Good Risk Cytogenetics Intermediate Risk Cytogenetics High/Poor Risk Cytogenetics

  125. Slide 125: Induction Therapy Used by Region

    Induction Therapy Used by Region 100% 100% 100% 100% 20% 20% 6% 11% 18% 27% 29% 13% 47% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% US Europe US Europe US Europe % Frequency of Mentions 7+3 Decitabine Azacitidine LD Ara-C Palliative Care Unfit for intensive Tx Poor/Int Risk Good Risk Source: Results

  126. Slide 126: Commercial Plan

    Commercial Plan for CPX - 351 126

  127. Slide 127: Building U.S. Commercialization Plans and Evaluating ex-U.S. Partnering

    Building U.S. Commercialization Plans and Infrastructure and Evaluating ex - U.S. Partnering Options U.S. Commercial Prep • KOL and Investigator Engagement • Positioning, Branding, Core Messages • PR • Value Proposition, Access, Reimbursement, and Pricing • Targeting and Segmentation • Staffing in k

  128. Slide 128: Transplant Centers Allow Modest Sales Footprint

    48 Centers Performed >70% of AML SCTs Allows Modest Sales Footprint to Cover Concentrated Target Base Department of Health and Human Services, Blood Transplant Report by Center; AML Acute myeloid leukemia - all disease states, number of transplants reported in 2012 website location -- http://bloodce

  129. Slide 129: Centers Participating in Phase 3 Trial

    48 Centers Performed >20 more AML SCTs in 2012 23 Participating in CPX - 351 Phase 3 Trial Department of Health and Human Services, Blood Transplant Report by Center; AML Acute myeloid leukemia - all disease states, number of transplants reported in 2012 website location -- http :// bloodcell.transp

  130. Slide 130: Favorable Physician and Payer Reactions to Target Product Profile

    Favorable Physician and Payer Reactions to CPX - 351 Target Product Profile • Physicians expressed positive reaction, with an overall rating 5.8 out of 7.0 • “It is a novel new agent with phenomenal complete remission. Recovery of blood count is later, but I don’t mind that. From my point of view th

  131. Slide 131: Value in AML and beyond

    Value of CPX - 351 in AML and beyond 131

  132. Slide 132: Projected Revenues in U.S. and Other Markets

    Projected Revenues in U.S. and Other Markets Reflect Significant Market Opportunity for CPX - 351 Initial indication of sAML >60 Additional labels and data in AML and other TOTAL United States $120 - 150M ~$290M $410 - 440M ROW $80 - 160M ~$200M $280 - 360M TOTAL $200 - 270M ~490M $690 - 780M Since

  133. Slide 133: Global Market Opportunities Support Life Cycle Plans

    Global Market Opportunities are Sufficient to Support Life Cycle Plans Figures are in $millions and represent projected market size

  134. Slide 134: An Attractive Commercial Opportunity

    CPX - 351 is an Attractive Commercial Opportunity • Unmet need in AML remains very high • CPX - 351 has the potential to become the standard of care in AML • Treatment patterns in US and key European markets appear to be very similar, allowing for Global Strategy Alignment • Concentrated target audi

  135. Slide 135: Question & Answer Session

    Question & Answer Session Celator Pharmaceuticals Analyst Day, July 17, 2014 135

  136. Slide 136: Closing Remarks

    Closing Remarks Scott Jackson Chief Executive Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 136

  137. Slide 137: Creating Shareholder Value

    Creating Shareholder Value • Execution of the Phase 3 study and preparation for regulatory submission and commercialization • Celator to commercialize CPX - 351 in the US • Seek ex - US partner • Continue to evaluate the potential of CPX - 351 in other patient populations (e.g. AML and other hematol

  138. Slide 138: Expected Milestones and News Flow

    138 Expected Milestones and News Flow Estimated dates for data availability from studies Phase 3 Completion of Enrollment Phase 3 Remission Rate Start Technology Platform Programs Phase 3 Overall Survival Complete Technology Platform Programs NDA Submission Technology Platform Programs - TBD 2Q 3Q 4

Celator Pharmaceuticals — Investor Day (July 2014) on 6ix